Pharmacovigilance (PV) is a challenging field and identifying and minimising risks is a complex process never more so than in early phase clinical trials. New adverse events (AEs) continue to be added to the list of expected events for a product years after it has been licensed and treated millions of people. So how can a Sponsor hope to characterise the safety of an Investigational Medicinal Product (IMP) during their early phase ‘safety’ studies, with such limited data and patient numbers? Why is it so important to get it right at this stage and what are the knock-on effects if it is done badly?
This webinar looks to highlight some of the major challenges of PV in early phase clinical trials and what can be done to overcome them. There will be a particular focus on oncology, where patients can be expected to have multiple complex and confounding comorbidities and treatments.
This session is designed for those starting out in their drug safety career in clinical trials, or those with post-marketing experience looking for a change in focus.
Not sure if you want to exhibit at or attend the The Challenges of Pharmacovigilance in Early Phase Clinical Trials? See the panels below to get the information you need to make an informed decision.
|Conference/Event Dates:||04/27/2016 - 04/27/2016|
|Primary Industry:||Clinical Pharmacology|
|Other Industries:||Clinical Pharmacology, Professional Healthcare|
|Audience:||Intermediate professionals who currently work in clinical trials, working in post marketing with an interest in PV.
Influencers or decisions makers in clinical trials who are interested in outsourcing PV.
Clinicians who may not be aware of the benefits of a targeted PV approach further down the developmental path of an IMP.
|Booth Size||Booth Cost||Available Amenities|
|Marketing Vehicles Allowed:||n/a|
|Other Booth Sizes Available: n/a|
How do I show up here?
Add a note here, it is only visible by you.